» Articles » PMID: 38961225

Sex-dependent APOE4 Neutrophil-microglia Interactions Drive Cognitive Impairment in Alzheimer's Disease

Abstract

APOE4 is the strongest genetic risk factor for Alzheimer's disease (AD), with increased odds ratios in female carriers. Targeting amyloid plaques shows modest improvement in male non-APOE4 carriers. Leveraging single-cell transcriptomics across APOE variants in both sexes, multiplex flow cytometry and validation in two independent cohorts of APOE4 female carriers with AD, we identify a new subset of neutrophils interacting with microglia associated with cognitive impairment. This phenotype is defined by increased interleukin (IL)-17 and IL-1 coexpressed gene modules in blood neutrophils and in microglia of cognitively impaired female APOE ε4 carriers, showing increased infiltration to the AD brain. APOE4 female IL-17 neutrophils upregulated the immunosuppressive cytokines IL-10 and TGFβ and immune checkpoints, including LAG3 and PD-1, associated with accelerated immune aging. Deletion of APOE4 in neutrophils reduced this immunosuppressive phenotype and restored the microglial response to neurodegeneration, limiting plaque pathology in AD mice. Mechanistically, IL-17F upregulated in APOE4 neutrophils interacts with microglial IL-17RA to suppress the induction of the neurodegenerative phenotype, and blocking this axis supported cognitive improvement in AD mice. These findings provide a translational basis to target IL-17F in APOE ε4 female carriers with cognitive impairment.

Citing Articles

Peripheral and central neuroimmune mechanisms in Alzheimer's disease pathogenesis.

Zhang S, Gao Y, Zhao Y, Huang T, Zheng Q, Wang X Mol Neurodegener. 2025; 20(1):22.

PMID: 39985073 PMC: 11846304. DOI: 10.1186/s13024-025-00812-5.


Identification of biomarkers in Alzheimer's disease and COVID-19 by bioinformatics combining single-cell data analysis and machine learning algorithms.

Li J, Tao L, Zhou Y, Zhu Y, Li C, Pan Y PLoS One. 2025; 20(2):e0317915.

PMID: 39965013 PMC: 11835241. DOI: 10.1371/journal.pone.0317915.


Identification of therapeutic targets for Alzheimer's Disease Treatment using bioinformatics and machine learning.

Xie Z, Situ Y, Deng L, Liang M, Ding H, Guo Z Sci Rep. 2025; 15(1):3888.

PMID: 39890844 PMC: 11785788. DOI: 10.1038/s41598-025-88134-w.


TGF-β Signaling in Microglia: A Key Regulator of Development, Homeostasis and Reactivity.

Li L, Sun B, Harris O, Luo J Biomedicines. 2024; 12(11).

PMID: 39595034 PMC: 11592028. DOI: 10.3390/biomedicines12112468.


Approaches for studying neuroimmune interactions in Alzheimer's disease.

Lin C, Tian Y, Tanzi R, Jorfi M Trends Immunol. 2024; 45(12):971-986.

PMID: 39537528 PMC: 11624993. DOI: 10.1016/j.it.2024.10.002.


References
1.
Belloy M, Napolioni V, Greicius M . A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. Neuron. 2019; 101(5):820-838. PMC: 6407643. DOI: 10.1016/j.neuron.2019.01.056. View

2.
Yin Z, Rosenzweig N, Kleemann K, Zhang X, Brandao W, Margeta M . APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints. Nat Immunol. 2023; 24(11):1839-1853. PMC: 10863749. DOI: 10.1038/s41590-023-01627-6. View

3.
Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R . The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017; 47(3):566-581.e9. PMC: 5719893. DOI: 10.1016/j.immuni.2017.08.008. View

4.
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland T . A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017; 169(7):1276-1290.e17. DOI: 10.1016/j.cell.2017.05.018. View

5.
Yin Z, Herron S, Silveira S, Kleemann K, Gauthier C, Mallah D . Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer's disease. Nat Neurosci. 2023; 26(7):1196-1207. PMC: 10619638. DOI: 10.1038/s41593-023-01355-y. View